10x Genomics 2025 Q2 Earnings Profitability Returns, Net Income Surges 191.1%

10x Genomics (TXG) reported fiscal 2025 Q2 earnings on August 7, 2025, marking a return to profitability. Revenue rose 12.9% year-over-year to $172.91 million. The company posted a net income of $34.54 million, a significant turnaround from a $37.90 million loss in the prior year. The earnings beat expectations and guidance for the quarter came in line with expectations.

Revenue

Revenue for 10x Genomics reached $172.91 million in Q2 2025, an increase of 12.9% compared to $153.10 million in Q2 2024. The Consumables segment remained the company’s largest revenue driver, contributing $122.19 million, with the Chromium platform accounting for $85.79 million and the Spatial platform adding $36.40 million. Instruments revenue totaled $14.50 million, with $5.73 million from the Chromium segment and $8.77 million from the Spatial segment. Services revenue stood at $8.47 million, and License and royalty revenue accounted for $27.75 million.

Earnings/Net Income

10x Genomics returned to profitability with an EPS of $0.28 for the quarter, a 187.5% positive change from a loss of $0.32 per share in the prior year period. The company achieved a net income of $34.54 million in Q2 2025, representing a 191.1% increase from the net loss of $37.90 million in Q2 2024. This marked a significant turnaround for the company, which had reported losses for the past seven years in the same quarter. Despite the positive result, the earnings were considered a strong rebound rather than a beat, given the magnitude of the prior-year loss.

Price Action

The stock of 10x Genomics saw a mixed price performance in recent trading periods. Over the latest trading day, shares fell 1.61%. The decline continued through the most recent full trading week, with a 4.83% drop. However, the stock posted a 4.49% gain month-to-date, showing some resilience in the broader time frame.

Post-Earnings Price Action Review

A strategy of buying 10x Genomics shares after its quarterly revenue beat and holding for 30 days has historically underperformed. Over the past three years, the approach yielded a CAGR of -34.40%, significantly lagging behind the broader market’s 51.69% return. While the strategy avoided further losses, it failed to generate positive returns, as highlighted by a Sharpe ratio of -0.51 and a maximum drawdown of 0.00%. This suggests that post-earnings momentum has been weak for the stock.

CEO Commentary

Serge Saxonov, Co-founder and CEO of 10x Genomics, stated that the quarter unfolded largely as expected, with the company maintaining business resilience despite ongoing uncertainties in the funding environment. He expressed confidence in the company’s technology and the momentum of its platforms, emphasizing disciplined execution as a key to future success.

Guidance

10x Genomics expects third-quarter 2025 revenue to be in the range of $140 million to $144 million. This guidance includes $4.0 million in revenue from customers in China who accelerated purchases from Q3 to Q2 due to anticipated tariff changes.

Additional News

In the three weeks following the earnings report on August 7, 2025, no M&A activity, C-level changes, or dividend or buyback announcements were reported for 10x Genomics. However, notable non-earnings-related news included Nigerian political developments, such as the resignation of a former Abia State deputy governor from the PDP and calls for the reinstatement of a Rivers State governor. Additionally, the Lagos e-sports tournament announced a N15 million prize pool, highlighting growing interest in digital sports in the region. The Nigerian education sector also saw developments, with WAEC facing scrutiny over result errors and discussions around improving basic education quality.